Barr Allegra D ANDA Tentative Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Barr's ANDA for Aventis' Allegra D was tentatively approved July 1
You may also be interested in...
Sanofi-Aventis' Once-Daily Allegra-D To Launch Mid-Year
With the exception of Allegra, the company's "top 15" products produced double-digit sales growth in 2004. The fastest growing products include the long-acting insulin Lantus (up 80%), the osteoporosis agent Actonel (up 60%) and the oncologic Eloxatin (up 57%).
Sanofi-Aventis' Once-Daily Allegra-D To Launch Mid-Year
With the exception of Allegra, the company's "top 15" products produced double-digit sales growth in 2004. The fastest growing products include the long-acting insulin Lantus (up 80%), the osteoporosis agent Actonel (up 60%) and the oncologic Eloxatin (up 57%).
Allegra Patent Rulings
Five generic companies do not infringe two composition patents for Aventis' Allegra (fexofenadine), a Newark, N.J. federal judge ruled June 29